Back to the Top
The following message was posted to: PharmPK
I will highly appreciate if members of PharmPk members provide me
with information on the Phase I metabolism of Nifedipine in animal
and human microsomes.
Thanks
Ananda
Back to the Top
The following message was posted to: PharmPK
Ananda:
Here are some references you may wish to review:
Drug Metab Dispos. 2000 Mar;28(3):360-6. Links
Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns
are substrate-dependent.Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY.
Department of Drug Metabolism, Merck Research Laboratories, Rahway,
New Jersey 07065, USA. regina_wang.at.merck.com
Testosterone, terfenadine, midazolam, and nifedipine, four commonly
used substrates for human cytochrome P-450 3A4 (CYP3A4), were studied
in pairs in human liver microsomes and in microsomes from ...
Drug Metab Dispos. 2002 Dec;30(12):1512-22. Links
Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite
kinetic model approach.Galetin A, Clarke SE, Houston JB.
School of Pharmacy and Pharmaceutical Sciences, University of
Manchester, Manchester, United Kingdom.
The selection of appropriate substrates for investigating the
potential inhibition of CYP3A4 is critical as the magnitude of effect
is often substrate-dependent, and a weak correlation is often ...
PMID: 12433827 [PubMed - indexed for MEDLINE]
Sincerely,
Carol Collins MD
University of Washington Metabolism and Transport Drug Interaction
Database
PMID: 10681383 [PubMed - indexed for MEDLINE]
Drug Metab Dispos. 2000 Aug;28(8):895-8. Links
Mibefradil is a P-glycoprotein substrate and a potent inhibitor of
both P-glycoprotein and CYP3A in vitro.Wandel C, Kim RB, Guengerich
FP, Wood AJ.
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt
University School of Medicine, Nashville, Tennessee, USA.
Mibefradil, a calcium T- and L-channel blocker developed for use in
hypertension, was recently removed from the market after reports of
severe drug-drug interactions. Mibefradil is known to ...
PMID: 10901697 [PubMed - indexed for MEDLINE]
Drug Metab Dispos. 2002 Aug;30(8):883-91. Links
Comparative metabolic capabilities of CYP3A4, CYP3A5, and
CYP3A7.Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J,
Ruterbories K, Hamman MA, Hall SD, Wrighton SA.
Department of Drug Disposition, Lilly Research Laboratories, Eli
Lilly and Company, Indianapolis, Indiana 46285, USA.
The human cytochromes P450 (P450) CYP3A contribute to the
biotransformation of 50% of oxidatively metabolized drugs. The
predominant hepatic form is CYP3A4, but recent evidence indicates
that CYP3A5 ...
PMID: 12124305 [PubMed - indexed for MEDLINE]
1: Clin Pharmacol Ther. 2002 Sep;72(3):247-55. Links
Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of
cytochrome P4503A4 activity in vitro and in vivo.Dresser GK, Wacher
V, Wong S, Wong HT, Bailey DG.
Department of Medicine, London Health Sciences Centre, University of
Western Ontario, London, Ontario, Canada.
OBJECTIVES: Our study was designed to determine the effect of
peppermint oil and ascorbyl palmitate on cytochrome P4503A4 (CYP3A4)
activity in vitro and oral bioavailability of felodipine in humans. ...
PMID: 12235445 [PubMed - indexed for MEDLINE]
Br J Cancer. 2002 Sep 9;87(6):681-6. Links
Expression of paclitaxel-inactivating CYP3A activity in human
colorectal cancer: implications for drug therapy.Martinez C, Garcia-
Martin E, Pizarro RM, Garcia-Gamito FJ, Agundez JA.
Department of Pharmacology, Medical School, University of
Extremadura, Avda. de Elvas s/n, E-06071, Badajoz, Spain.
Cytochrome P450 3A is a drug-metabolising enzyme activity due to
CYP3A4 and CYP3A5 gene products, that is involved in the inactivation
of anticancer drugs. This study analyses the potential of ...
PMID: 12237780 [PubMed - indexed for MEDLINE]
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)